

> Rationale


# PA CATHETER AND TAILORED THERAPY

### Rationale

• Cardiac output (CO) = SV × HR; optimize SV (and thereby CO) by manipulating preload/ LVEDV (w/ IVF, diuretics), contractility (w/ inotropes), & afterload (w/ vasodilators)

• Balloon at catheter tip inflated → floats into “wedge” position. Column of blood extends from tip of catheter, through pulm venous circulation to a point just prox to LA. Under conditions of no flow, PCWP ≈ LA pressure ≈ LVEDP, which is proportional to LVEDV.

• Situations in which these basic assumptions fail:

(1) Catheter tip not in West lung zone 3 (and ∴ PCWP = alveolar pressure ≠ LA pressure); clues include lack of _a_ & _v_ waves and if PA diastolic pressure < PCWP

(2) PCWP > LA pressure (eg, mediastinal fibrosis, pulmonary VOD, PV stenosis)

(3) Mean LA pressure > LVEDP (eg, MR, MS)

(4) ∆ LVEDP-LVEDV relationship (ie, 異常 compliance, ∴ “nl” LVEDP may not be optimal)

### Indications (_Circ_ 2009;119:e391; _NEJM_ 2013;369:e35)

• **Diagnosis and evaluation**

Ddx of shock (cardiogenic vs. distributive; espec if trial of IVF failed or is high risk) and of pulmonary edema (cardiogenic vs. not; espec if trial of diuretic failed or is high risk)

Evaluation of CO, intracardiac shunt, pulm HTN, MR, tamponade, cardiorenal syndrome

Evaluation of unexplained dyspnea (PAC during provocation with exercise, vasodilator)

• **Therapeutics** (_Circ_ 2006;113:1020)

Tailored therapy to optimize PCWP, SV, SMVO2, RAP, PVR in heart failure or shock

Guide to vasodilator therapy (eg, inhaled NO, nifedipine) in PHT, RV infarction

Guide periop mgmt in some high-risk 病人, candidacy for mech circ support & transplant

• **Contraindications**

**Absolute:** right-sided endocarditis, thrombus/mass or mechanical valve; proximal PE

**Relative:** coagulopathy (reverse), recent PPM or ICD (place under fluoroscopy), LBBB (~5% risk of RBBB → CHB, place under fluoro), bioprosthetic R-sided valve

### Efficacy concerns (_NEJM_ 2006;354:2213; _JAMA_ 2005;294:1664)

• No benefit to routine PAC use in high-risk surgery, sepsis, ARDS

• No benefit in decompensated HF (_JAMA_ 2005;294:1625); untested in cardiogenic shock

• But: ~1/2 of _clinical_ CO & PCWP estimates incorrect; CVP & PCWP not well correl.; ∴ use PAC to (a) answer hemodynamic ? and then remove, or (b) manage cardiogenic shock

### Placement (_NEJM_ 2013;369:e35)

• Insertion site: **R internal jugular** or **L subclavian veins** for “anatomic” flotation into PA

• **Inflate** balloon (max 1.5 mL) when **advancing** and to **measure PCWP**

• Use resistance to inflation and pressure tracing to avoid overinflation & risk of PA rupture

• **Deflate** the balloon when **withdrawing** and at all other times

• CXR should be obtained after placement to assess for catheter position and PTX

• If catheter cannot be floated (i.e., severe TR, RV dilatation), consider fluoroscopic guidance

### Complications

• **Central venous access:** pneumo/hemothorax (~1%), arterial puncture (if inadvertent cannulation with dilation → surgical/endovasc eval), air embolism, thoracic duct injury

• **Advancement:** atrial or ventricular arrhythmias (3% VT; 20% NSVT and >50% PVC), RBBB (5%), catheter knotting, cardiac perforation/tamponade, PA rupture

• **Maintenance:** infection (espec if catheter >3 d old), thrombus, pulm infarction (≤1%), valve/chordae damage, PA rupture/pseudoaneurysm (espec with PHT), balloon rupture

### Intracardiac pressures

• Transmural pressure (≈ preload) = measured intracardiac pressure – intrathoracic pressure

• Intrathoracic pressure (usually slightly ⊖) is transmitted to vessels and heart

• **Always measure intracardiac pressure at end-expiration**, when intrathoracic pressure closest to 0 (“high point” in spont. breathing 病人; “low point” in 病人 on ⊕ pressure vent.)

• If ↑ intrathoracic pressure (eg, PEEP), measured PCWP _overestimates_ true transmural pressures. Can approx by subtracting ~1/2 PEEP (× ¾ to convert cm H2O to mmHg).

• PCWP: LV preload best estimated at _a_ wave; risk of pulmonary edema from avg PCWP

### Cardiac output

• **Thermodilution:** saline injected in RA or prox thermal filament. ∆ in temp over time measured at thermistor (in PA) used to calc CO. Inaccurate if ↓ CO, sev TR, or shunt.

• **Fick method:** O2 consumption ![](https://i.imgur.com/cSTI2ay.jpg) (L/min) = CO (L/min) × ∆ arteriovenous O2 content

∴ **CO** = ![](https://i.imgur.com/hOkQGr8.jpg)**/ C(a-v)O2**

![](https://i.imgur.com/cSTI2ay.jpg) ideally measured (esp. if ↑ metab demands), but freq estimated (125 mL/min/m2)

C(a-v)O2 = \[10 × 1.36 mL O2/g of Hb × Hb g/dL × (SaO2 – SMVO2)\]. _S_MV_O_2 _is key var that_ ∆_s._

If SMVO2 >80%, consider if the PAC is “wedged” (ie, pulm vein sat), L→R shunt, impaired O2 utilization (severe sepsis, cyanide, carbon monoxide), ↑↑ FiO2.

![](https://i.imgur.com/BRdUG17.jpg)

PCWP waveform abnormalities: large _a_ wave → ? mitral stenosis; large _v_ wave → ? mitral regurgitation; blunted _y_ descent → ? tamponade; steep _x_ & _y_ descents → ? constriction.

![](https://i.imgur.com/LWUNltl.jpg)

Surrogates: RA ≈ JVP (1 mmHg = 1.36 cm H2O); pulmonary edema on CXR implies ↑ PCWP; UOP ∝ CO (barring AKI); delayed capillary refill (ie, >2–3 sec) implies ↑ SVR

### Tailored therapy in cardiogenic shock (_Circ_ 2009;119:e391)

• **Goals:** optimize both MAP and CO while ↓ risk of pulmonary edema

MAP = CO × SVR; CO = HR × SV (which depends on preload, afterload, and contractility)

pulmonary edema when PCWP >20–25 (↑ levels may be tolerated in chronic HF)

hepatic and renal congestion when CVP/RAP >15 mmHg

• **Optimize preload** = LVEDV ≈ LVEDP ≈ LAP ≈ PCWP (_NEJM_ 1973;289:1263)

goal **PCWP** ~**14–18 in acute MI**, **≤14 in acute decompensated HF**

optimize in individual Pt by measuring SV with different PCWP to create Starling curve

↑ by giving NS (albumin without 臨床benefit over NS; PRBC if significant anemia)

↓ by diuresis (qv), ultrafiltration or dialysis if refractory to diuretics

• **Optimize afterload** ≈ wall stress during LV ejection = \[(~SBP × radius) / (2 × wall thick.)\] and ∴ ∝ MAP and ∝ SVR = (MAP – CVP / CO); goals: **MAP** >**60**, **SVR 800–1200**

MAP >60 & SVR ↑: vasodilators (eg, nitroprusside, NTG, ACEI, hydral.) or wean pressors

MAP <60 & SVR ↑ (& ∴ CO ↓): temporize with pressors until can ↑ CO (see below)

MAP <60 & SVR low/nl (& ∴ inappropriate vasoplegia): vasopressors (eg, norepinephrine \[α, β\], dopamine \[D, α, β\], phenylephrine \[α\] or vasopressin \[V1\] if refractory); better outcomes with norepi than dopa even in cardiogenic shock (_NEJM_ 2010;362:779)

• **Optimize contractility** ∝ CO for given preload & afterload; **goal CI** = **(CO / BSA) >2.2**

if too low despite optimal preload & vasodilators (as MAP permits):

⊕ _inotropes:_ eg, dobutamine (mod inotrope & mild vasodilator) or milrinone (strong inotrope & vasodilator, incl pulm), both proarrhythmic, or epi (strong inotrope & pressor)

_mech circulatory support (L/min):_ IABP (0.5), Impella (2–5), TandemHeart (5), VAD (L-sided, R-sided or both; temp or perm; 10) or ECMO (6) (_JACC_ 2015;65:e7 & 2542)
